Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Urologic Oncology|March 29, 2022
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinomaTaizo Uchimoto, Ko Nakamura, Kazumasa Komura, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2026
A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortiumTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
BJU International|July 24, 2020
Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Nature Communications|January 17, 2023
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerTakuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, et al.
Journal of Clinical Medicine|August 22, 2019
Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter CohortKazumasa Komura, Yuya Fujiwara, Taizo Uchimoto, et al.
Japanese Journal of Clinical Oncology|August 23, 2024
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapyShingo Toyoda, Wataru Fukuokaya, Keiichiro Mori, et al.
Medical Oncology (Northwood, London, England)|November 23, 2019
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancerTaizo Uchimoto, Kazumasa Komura, Yuya Fujiwara, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 19, 2025
Extended Follow-Up of Robot-Assisted Partial Nephrectomy for Renal Hilar Tumor: A Prospective Multi-Institutional Study (ROBOHIT Trial)Jun Teishima, Ryoichi Shiroki, Toshio Takagi, et al.
International Journal of Clinical Oncology|September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumabKeiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Cancers|February 12, 2021
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate CancerTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.
Pageof 9